Related Experiment Videos
Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A)
Abstract:
The activity of the alpha interferons against AIDS-related Kaposi's sarcoma (KS) has been demonstrated in numerous clinical trials. Unfortunately, most reports have involved small patient cohorts and a variety of dosages and schedules of administration. We report here a series of Phase II trials with interferon alfa-2b (Intron A, Schering Corp., Kenilworth, NJ) involving 114 patients using three dose regimens. Patients received 50 X 10(6) IU/m2 intravenously (high dose), 30 X 10(6) IU/m2 subcutaneously (intermediate dose), or 1 X 10(6) IU/m2 subcutaneously (low dose). Clinical responses were seen in all regimens and, overall, 35% of the patients obtained complete or partial remissions. The response rates in the low-, intermediate-, and high-dose groups were 33%, 28%, and 45%, respectively. In addition, high-dose therapy was associated with more rapid time to response. Patients with low-stage (I or II) disease and those who lack B symptoms were more likely to respond to therapy; i.e., response rates for patients without B symptoms were 38%, 44%, and 60% in the low-, intermediate-, and high-dose groups, respectively. Seventy (61%) patients had died at the time of data collection, with a median survival of 15 months. Disease stage and the presence of B symptoms significantly affected mortality. Responders enjoyed significantly longer survival (P less than 0.10) than did nonresponders both overall and when adjusted for disease stage. Interferon alfa-2b was generally well tolerated, although almost all patients experienced flu-like symptoms. No life-threatening toxicities occurred and only six (6%) patients discontinued treatment due to adverse reactions. No significant improvement in immunologic parameters was detected during this study. These studies suggest that, in this disease setting, interferon alfa-2b may be acting through direct antiproliferative effects rather than as an immunomodulator, and higher doses appear to be more effective than very low doses.
Insights
Interferon alfa-2b showed effectiveness against AIDS-related Kaposi's sarcoma across various doses. Higher doses led to quicker responses and better outcomes, suggesting direct anti-cancer effects.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Alpha interferons have shown promise against AIDS-related Kaposi's sarcoma (KS).
- Previous studies often used small patient groups and varied treatment protocols.
- Standardized trials are needed to evaluate interferon alfa-2b efficacy and dosing.
Purpose of the Study:
- To assess the efficacy of interferon alfa-2b in patients with AIDS-related Kaposi's sarcoma.
- To compare three different dose regimens of interferon alfa-2b.
- To evaluate the impact of dose, disease stage, and symptoms on treatment response and survival.
Main Methods:
- Phase II clinical trials involving 114 patients with AIDS-related Kaposi's sarcoma.
- Three treatment groups received interferon alfa-2b: high-dose intravenous (50 X 10(6) IU/m2), intermediate-dose subcutaneous (30 X 10(6) IU/m2), or low-dose subcutaneous (1 X 10(6) IU/m2).
- Clinical responses, survival rates, and adverse events were monitored.
Main Results:
- Overall, 35% of patients achieved complete or partial remission.
- Response rates were 33% (low dose), 28% (intermediate dose), and 45% (high dose).
- High-dose therapy correlated with a faster response time. Patients with early-stage disease and without B symptoms showed better response rates. Responders had significantly longer survival.
- Interferon alfa-2b was generally well-tolerated, with flu-like symptoms being the most common side effect. No significant immunologic improvements were observed.
Conclusions:
- Interferon alfa-2b is an effective treatment for AIDS-related Kaposi's sarcoma.
- Higher doses of interferon alfa-2b appear more effective and lead to faster responses.
- The drug likely acts via direct antiproliferative effects rather than immunomodulation in this context.